The Latest Malaria News, in 60 Seconds.

Researchers evaluate the immunogenicity of the AGS-v vaccine which targets saliva produced by Anopheles gambiae mosquitoes.

Malaria Minute on iTunes and Spotify


Whilst many of the vaccine candidates against malaria aim to provide protection against Plasmodium parasites, to date there has not been a vaccine evaluated in humans targeted towards the mosquito itself. Preclinical studies have suggested that antibodies to mosquito saliva may provide some protection against mosquito-borne diseases, and this could also apply to malaria. In a new clinical trial, researchers assessed the immunogenicity of the AGS-v vaccine, which aims to induce antibodies against saliva produced by Anopheles gambiae, the main malaria vector in Africa. 49 participants were assigned to either a vaccine-only group, an adjuvanted vaccine group or a placebo group. The vaccine was well-tolerated in all cases and most immunogenic when given with adjuvant, resulting in a significant increase in vaccine-specific IgG antibodies and also the cytokines interferon-gamma. If the vaccine provides protection, it could help to control malaria.


Safety and Immunogenicity of a Mosquito Saliva Peptide-Based Vaccine: A Randomised, Placebo-Controlled, Double-Blind, Phase 1 Trial

Image Credits: CDC/ James Gathany [18754]

Scientific Advisor: Katharine Collins, Radboud University Medical Centre

Categories: Malaria Minute